melanoma

Oncology

Interview at ESMO 2025 with Inge Marie Svane

ESMO25: Immuno-therapies and translational research in oncol...

Dr Inge Marie Svane – Professor in Clinical cancer immune therapy and director of the translational research centre, CCIT, on IO Biotech's ESMO25 data

News

IO Bio plans cancer vaccine filing despite trial miss

IO Biotech's cancer vaccine Cylembio failed to hit the mark in a phase 3 melanoma trial – but the company hopes to file for approval regardless.

News

Iovance cuts staff on slower cell therapy sales growth

Iovance will slash 19% of its headcount in a restructuring that follows slower-than-expected sales growth for melanoma cell therapy Amtagvi.

Oncology

Redefining the future of melanoma treatment: Scancell's bold...

News

Scancell points to 'strong' melanoma vaccine data

Scancell has the results it was hoping for with its melanoma immunotherapy iSCIB1+ and is accelerating plans for a pivotal trial.

News

Scancell taps into NHS matchmaking service for cancer trial

Scancell is using a new service launched by the NHS to pair patients with suitable clinical trials in a phase 2 trial of its melanoma cancer vaccine.

ESMO25: Immuno-therapies and translational research in oncol...

IO Bio plans cancer vaccine filing despite trial miss

Iovance cuts staff on slower cell therapy sales growth

Redefining the future of melanoma treatment: Scancell's bold...

Scancell points to 'strong' melanoma vaccine data

Scancell taps into NHS matchmaking service for cancer trial

Ambros' $125m for pain disorder drug, and other financings

How to meet your physicians where they are online

melanoma

Editor's Picks